

November 25, 2022

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

**Ref: Scrip Name: GLENMARK** 

Dear Sirs,

## Sub: Disclosure of Related Party Transactions for the half year ended 30th September, 2022

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions for the half year / six months ended 30th September, 2022.

The same is also being made available on the website of the Company at www.glenmarkpharma.com

Thanking you.

Yours faithfully, For Glenmark Pharmaceuticals Limited

Harish Kuber Company Secretary & Compliance Officer

Encl: As above

						Disclosure of Related Party Transactions for the	e half year ended 30	th September 202	2					_	
													Additional discl advances or inv		
													when such tran		
											In case monies a	re due to either			
	Details of the party entering into the transaction	n	Details of the counterp	arty							party as a result	of the transaction			
Sr.							Details of other	Remarks on approval by	Value of the related party transaction as	Value of transaction			is incurred to m inter-corporate		
No.						Type of related party transaction	Related Party Transactions	audit	approved by the audit	during the reporting period			or investments		, advance
				1	1			committee	committee					Τ	Τ
					Relationship of the						Opening		Nature of indebtedness		
	Name	PAN	Name	PAN	counterparty with the listed						balance	Closing balance (30.09.2022)	(loan/ issuance	e Cost	Tenure
					entity						(01.04.2022)	. ,	of debt/ any other etc.)		
1	Glenmark Pharmaceuticals Limited		Ichnos Sciences SA		Wholly Owned Subsidiary	Sale of material & services			Not applicable	0.13	3			+	+
2	Glenmark Pharmaceuticals Limited		Glenmark Farmaceutica Ltda.		Wholly Owned Subsidiary	Sale of material & services			Not applicable	444.35				1	1
3	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Phillipines Inc. Glenmark Impex L.L.C.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of material & services Sale of material & services	+		Not applicable Not applicable	173.28	5			+	┼──
5	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals South Africa (Pty) Ltd.		Wholly Owned Subsidiary	Sale of material & services			Not applicable	56.30					
6	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Peru SAC. Glenmark Pharmaceuticals (Thailand) Co. Ltd.		Wholly Owned Subsidiary Joint Venture	Sale of material & services Sale of material & services			Not applicable Not applicable	16.62				+	
8	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Kenya Ltd		Wholly Owned Subsidiary	Sale of material & services			Not applicable	281.15				1	1
9 10	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Colombia Ltda. Glenmark Pharmaceuticals Mexico, S.A. DE C.V.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of material & services Sale of material & services			Not applicable Not applicable	14.27				+	
11			Glenmark Pharmaceuticals Malaysia Sdn Bhd.		Wholly Owned Subsidiary	Sale of material & services			Not applicable					—	<u> </u>
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Inc. Glenmark Pharmaceuticals s.r.o.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of material & services Sale of material & services			Not applicable Not applicable	1,405.38				+	
14			Glenmark Pharmaceuticals Europe Ltd.		Wholly Owned Subsidiary	Sale of material & services			Not applicable	947.32				—	<u> </u>
15 16	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Ecuador S.A. Glenmark Therapeutics Inc.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of material & services Sale of material & services			Not applicable Not applicable	43.83				<u>+</u>	
17	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Canada Inc.	F	Wholly Owned Subsidiary	Sale of material & services			Not applicable	117.07				$\square$	F
-	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Specialty S.A. Glenmark Arznimittel Gmbh		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of material & services Sale of material & services			Not applicable Not applicable	1,486.35				<u>+</u>	
20	Glenmark Pharmaceuticals Limited		Glenmark Life Sciences Ltd.	F	Subsidiary	Sale of material & services			10,000.00	81.57				$\square$	F
21 22	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Ichnos Sciences SA Glenmark Specialty S.A.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Other Operating Income Other Operating Income			Not applicable Not applicable	1.16				$\pm$	$\mathbf{t}$
23	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Inc.		Wholly Owned Subsidiary	Other Operating Income	[		Not applicable	36.57	7	[	[	—	<b>—</b>
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Inc. Glenmark Pharmaceuticals FZE.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements) Purchase of materials & services (inclusive reimbursements)			Not applicable Not applicable	453.04 138.43				$\pm$	$\mathbf{t}$
26	Glenmark Pharmaceuticals Limited		Glenmark Farmaceutica Ltda.		Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements)	[		Not applicable	108.58 224.97	3	[	[	—	<b>—</b>
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Europe Ltd. Glenmark Impex L.L.C.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements) Purchase of materials & services (inclusive reimbursements)			Not applicable Not applicable	224.97 753.79				$\pm$	$\vdash$
	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals s.r.o.		Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements)			Not applicable	169.45				—	<u> </u>
30 31		-	Glenmark Specialty S.A. Glenmark Pharmaceuticals Kenya Ltd.	-	Wholly Owned Subsidiary Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements) Purchase of materials & services (inclusive reimbursements)			Not applicable Not applicable	3.66		-	-	+	<u> </u>
32			Glenmark Singapore Pte Ltd		Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements)			Not applicable	28.15				1	1
33 34			Glenmark Arznimittel Gmbh Glenmark Ukraine LLC		Wholly Owned Subsidiary Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements) Purchase of materials & services (inclusive reimbursements)			Not applicable Not applicable	21.98				+	+
35	Glenmark Pharmaceuticals Limited		Glenmark Life Sciences Ltd		Subsidiary	Purchase of materials & services (inclusive reimbursements)			10,000.00	2,995.47					
36	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Ichnos Sciences Inc. Piramal Pharma Ltd.		Wholly Owned Subsidiary Other related party	Purchase of materials & services (inclusive reimbursements) Purchase of materials & services (inclusive reimbursements)			Not applicable 250.00	1.51				+	+
38	Glenmark Pharmaceuticals Limited		Trilegal		Other related party	Purchase of services			15.00	1.82				1	1
39 40			Glenmark Pharmaceuticals (Australia) Pty Ltd. Glenmark Pharmaceuticals Peru SAC.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Investment in share capital Investment in share capital			Not applicable Not applicable	11.04				+	+
41	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Colombia Ltda.		Wholly Owned Subsidiary	Share Application Money			Not applicable	20.19					
42	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Holding S.A. Glenmark Pharmaceuticals Egypt S.A.E.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Loan given	+		Not applicable Not applicable	6,364.92				+	
-15	Glenmark Pharmaceuticals Limited		Glenmark Holding S.A.		Wholly Owned Subsidiary	Loan given to subsidiary converted into Investment			Not applicable	17,697.67				1	
44 45	Glenmark Pharmaceuticals Limited		Glenmark Holding S.A.		Wholly Owned Subsidiary	Loan repaid by subsidiary			Not applicable	9.405.83	8			+	<u> </u>
46	Glenmark Pharmaceuticals Limited		Glenmark Holding S.A.		Wholly Owned Subsidiary	Interest Income			Not applicable	932.32	2				
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals (Nigeria) Ltd. Glenmark Pharmaceuticals Kenva Ltd.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Interest Income Interest Income			Not applicable Not applicable	2.69				+	
	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals (Thailand) Co. Ltd.		Joint Venture	Interest Income			Not applicable					1	
50 51	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Egypt S.A.E. Glenmark Holding S.A.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Interest Income Other Income			Not applicable Not applicable					+	
	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals s.r.o.		Wholly Owned Subsidiary	Other Income			Not applicable	0.61				1	
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Inc. Glenmark Lifescience Limited		Wholly Owned Subsidiary Subsidiary	Other Income Other Income	+		Not applicable 10,000.00	12.79				+	
55	Glenmark Pharmaceuticals Limited	1	Glenmark Foundation	1	Other related parties	Contribution incurred for CSR activities			300.00	55.28	3			+	<u> </u>
56 57		+	Glenmark Aquatic Foundation Mr. Glenn Saldanha	-	Other related parties Chairman & Managing Director	Contribution incurred for CSR activities Remuneration paid			100.00 Approved	31.22				+	+
58	Glenmark Pharmaceuticals Limited		Mrs. Cherylann Pinto		Executive Director	Remuneration paid	[		Approved	19.65	i i	[	[	—	<b>—</b>
59 60	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Mr V S Mani Mr. Harish Kuber		Executive Director Company Secretary & Complia	Remuneration paid Remuneration paid	+		Approved Approved	67.27		1		+	+
	Glenmark Pharmaceuticals Limited		Mrs. Blanche Saldanha	1	Non Executive - Non	Sitting Fees			Not applicable	0.20				1	
61 62	Glenmark Pharmaceuticals Limited		Mr. D.R. Mehta		Independent Director Independent Director	Sitting Fees			Not applicable	1.20				$\pm$	$\mathbf{t}$
63	Glenmark Pharmaceuticals Limited		Mr. Rajesh Desai	[	Independent Director	Sitting Fees			Not applicable	0.90	0			1	$\square$
_	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Mr. Sridhar Gorthi Mr. Brian Tempest		Independent Director Independent Director	Sitting Fees Sitting Fees	+		Not applicable Not applicable	0.80		1		+	+
66	Glenmark Pharmaceuticals Limited		Mr. Bernard Munos	[	Independent Director	Sitting Fees			Not applicable	0.30	0			1	$\square$
67 68	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Mrs. Sona Saira Ramasastry Mr. Dipankar Bhattacharjee	-	Independent Director Independent Director	Sitting Fees Sitting Fees			Not applicable Not applicable	0.70		-	-	+	+
69	Glenmark Pharmaceuticals Limited		Glenmark Arzneimittel GmbH		Wholly Owned Subsidiary	Payable			Not applicable		0.00			-	<b>—</b>
70 71	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	L	Glenmark Farmaceutica Ltda. Glenmark Philippines Inc.	L	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Receivable			Not applicable Not applicable		1,375.60			<u>+</u>	
72	Glenmark Pharmaceuticals Limited		Ichnos Sciences SA		Wholly Owned Subsidiary	Receivable	[		Not applicable		99.15	108.2	1	—	<b>—</b>
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Holding S.A. Ichnos Sciences Biotherapeutics S.A		Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Receivable			Not applicable Not applicable		70,374.18			<u>+</u>	
75	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals (Nigeria) Ltd.	F	Wholly Owned Subsidiary	Receivable			Not applicable		395.47 635.66	7 429.24		$\square$	
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Impex L.L.C. Glenmark Impex L.L.C.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Payable		<u> </u>	Not applicable Not applicable		0.00	283.4	i		
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	1	Glenmark Pharmaceuticals South Africa (Pty) Ltd.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable			Not applicable		244.57			+	+
79 80			Glenmark Pharmaceuticals FZE. Glenmark Generics SA.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Payable Receivable		<u> </u>	Not applicable Not applicable		0.48	3 0.5	2		
81 82	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Glenmark Pharmaceuticals Venezuela. C.A Glenmark Pharmaceuticals Malavsia Sdn.Bhd.		Wholly Owned Subsidiary	Receivable Receivable			Not applicable		1,558.20			+	+
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Malaysia Sdn.Bhd. Glenmark Pharmaceuticals Peru SAC.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable		<u> </u>	Not applicable Not applicable		49.56	5 52.3	7		
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Inc.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Payable Receivable	+		Not applicable Not applicable		2,123.68			+	+
86	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals s.r.o.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable			Not applicable		1,013.68	1,341.1	1	$\pm$	$\mathbf{t}$
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Glenmark Therapeutics Inc. Glenmark Pharmaceuticals SK, s.r.o.	<u> </u>	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Payable	+		Not applicable Not applicable	<u>_</u>	3.94			+	+
89	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals SP Zoo		Wholly Owned Subsidiary	Payable			Not applicable		0.16	0.1	7	$\pm$	1
90	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Glenmark Pharmaceuticals (Thailand) Co. Ltd. Glenmark Uruguay S.A.	<u> </u>	Joint Venture Wholly Owned Subsidiary	Receivable Payable	+		Not applicable Not applicable		24.39			+	+
01	Signmark i narmaceuticais cimited			1			1		Not applicable	l	47.60			+	+
91 92	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Colombia Ltda.		Wholly Owned Subsidiary	Receivable			Not applicable		47.00	52.8			

					₹ in Million	
ed part	ty transactions - ap	plicable only in cas	e the related party	transaction relates	to loans, inter-corporate deposits,	
de or g	iven by the listed e				once, during the reporting period	Notes
underta	ken.					
	Details of the loan	s inter-corporate (	deposits, advances	or investments		
dness	Details of the loan	s, inter-corporate t	deposits, advances	or investments		
oans, vances						
Vances						
			1			
	Nature (loan/					
	advance/ inter-			Secured/	Purpose for which the funds will	
nure	corporate	Interest Rate (%)	Tenure	unsecured	be utilised by the ultimate	
	deposit/ investment				recipient of funds (end-usage)	
	investment					
			1			
	Investment	Not applicable	Not applicable	Not applicable	Business purpose	
	Invectment	Not applicable	Not applicable			
	Investment	Not applicable	Not applicable	Not applicable		
	Loan	4.50%	5 Years	Not applicable Unsecured	Business purpose Business purpose	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose	
	Loan	4.50%	5 Years	Not applicable Unsecured	Business purpose Business purpose	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	
	Loan Loan	4.50% 11.71%	5 Years 3 years	Not applicable Unsecured Unsecured	Business purpose Business purpose Working capital requirement	

94	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Mexico S.A. DE C.V.	Wholly Owned Subsidiary	Receivable		Not appl		200.13	184.50	$\square$	
95 96	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Egypt S.A.E. Glenmark Pharmaceuticals Canada Inc.	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Receivable		Not appl Not appl		152.66 173.71	247.74 316.61	 ——	
97	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals B.V.	Wholly Owned Subsidiary	Payable		Not appl		0.01	0.01		
98	Glenmark Pharmaceuticals Limited	Glenmark Specialty S.A.	Wholly Owned Subsidiary	Receivable Receivable	-	Not appl Not appl		3,587.02 314.04	5,284.85 229.23	 ——	_
	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	Glenmark Ukraine LLC Glenmark Pharmaceuticals Ecuador S.A.	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable		Not appl Not appl		84.74	95.46	+-	
101	Glenmark Pharmaceuticals Limited	Glenmark Singapore Pte Ltd	Wholly Owned Subsidiary	Payable		Not appl		49.69	41.84	$\square$	_
102 103	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	Ichnos Sciences Inc. Piramal Pharma Limited	Wholly Owned Subsidiary Other related party	Receivable Receivable		Not appl Not appl		5.48	7.45 12.76	 	+
104	Glenmark Pharmaceuticals Limited	Glenmark Life Sciences Ltd.	Subsidiary	Payable		Not appl	able	2,697.43	2,526.29		-
105 106	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	Glenmark Holding SA	Wholly Owned Subsidiary	Corporate Guarantee Corporate Guarantee		Not appl Not appl		15,859.20 9,440.00	17,112.90 10,186.25	 <u> </u>	_
	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Inc Glenmark Life Sciences Limited	Wholly Owned Subsidiary Subsidiary	Corporate Guarantee		Not appl Not appl		3,850.00	3,850.00		+
108	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Distribution s.r.o.	Wholly Owned Subsidiary	Corporate Guarantee		Not appl		516.00	487.50	$\square$	_
109 110	Ichnos Sciences Inc.	Ichnos Sciences SA Ichnos Sciences SA	Fellow Subsidiary Fellow Subsidiary	Long term Loan Long term Loan repaid		Not appl Not appl				 	+
	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Misc Income		Not appl					
	Ichnos Sciences Inc. Ichnos Sciences Inc.	Ichnos Sciences SA Glenmark Holding S.A.	Fellow Subsidiary Fellow Subsidiary	Interest Income Dividend Accrued		Not appl Not appl				 <u> </u>	_
	Ichnos Sciences Inc.	Glenmark Pharmaceuticals Inc	Fellow Subsidiary	Payable		Not appl		128.27	138.41		+
	Ichnos Sciences Inc.	Glenmnark Holding SA	Fellow Subsidiary	Dividend Payable		Not appl		2,746.93	4,005.13	$\square$	_
116 117	Ichnos Sciences Inc.	Ichnos Sciences Biotherapeutics SA Ichnos Sciences SA	Fellow Subsidiary Fellow Subsidiary	Payable Payable		Not appl Not appl		0.00	2.31	 —	-
118	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Receivable		Not appl	able	1,552.08	1,836.27		
119 120	Ichnos Sciences Inc. Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA Ichnos Sciences SA	Fellow Subsidiary Fellow Subsidiary	Loans to related party Misc Income		Not appl Not appl		0.00	2,559.07	 <u> </u>	+
120	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Receivable		Not appl		739.34	740.15		
122	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Payable		Not appl		1.88	0.58	 $\rightarrow$	_
123 124	Glenmark Pharmaceuticals Sp. z o.o. Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Fellow Subsidiary Fellow Subsidiary	Sale of material & services Receivable		Not appl Not appl		193.12	88.72	 	+
125	Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Pharmaceuticals s.r.o.	Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements)		Not appl	able 274.66				
126	Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Pharmaceuticals s.r.o.	Fellow Subsidiary	Payable Exponent Paid by others on hehalf		Not appl		458.49	397.19	 <u> </u>	_
127 128	Glenmark Pharmaceuticals Sp. z o.o. Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Distributor s.r.o.	Fellow Subsidiary Fellow Subsidiary	Expenses Paid by others on behalf Sale of material & services	1	Not appl Not appl				 +-	+
129	Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Pharmaceuticals Distributor s.r.o.	Fellow Subsidiary	Receivable		Not appl	able	0.51	1.02		エ
130 131	Glenmark Pharmaceuticals Sp. z o.o. Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Pharmaceuticals Distributor s.r.o. Glenmark Pharmaceuticals Distributor s.r.o.	Fellow Subsidiary Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements) Payable	-	Not appl Not appl		30.30	26.46	 <u> </u>	+
131	Glenmark Pharmaceuticals Sp. 2 0.0. Glenmark Pharmaceuticals Sp. 2 0.0.	Glenmark Pharmaceuticals Distributor s.r.o. Glenmark Pharmaceuticals Malaysia Sdn Bhd	Fellow Subsidiary	Sale of material & services		Not appl Not appl		50.30	20.40		_
133	Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Pharmaceuticals Malaysia Sdn Bhd	Fellow Subsidiary	Receivable	1	Not appl	able	-	0.67	—	キ
134 135	Glenmark Pharmaceuticals Sp. z o.o. Glenmark Pharmaceuticals Sp. z o.o.	Glenmark Holding S.A. Glenmark Holding S.A.	Fellow Subsidiary Fellow Subsidiary	Loan received Interest paid	+	Not appl Not appl		175.71	189.69	 +-	
136	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary	Sale of material & services	1	Not appl	able 10.72				ナ
137 138	Glenmark Pharmaceuticals Distributor s.r.o. Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals SK SRO Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary Fellow Subsidiary	Expenses paid on behalf of others Receivable		Not appl Not appl		6.96	4.52	 $\rightarrow$	+
138	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Ukraine LLC	Fellow Subsidiary	Expenses paid on behalf of others		Not appl		0.50	4.52		+
	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Ukraine LLC	Fellow Subsidiary	Receivable		Not appl		-	0.01	$\square$	_
141 142	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals sro. Glenmark Pharmaceuticals sro.	Fellow Subsidiary Fellow Subsidiary	Sale of material & services Receivable		Not appl Not appl		283.03	245.84	 	+
143	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals sro.	Fellow Subsidiary	Expenses paid on behalf of others		Not appl	able 2.39				
144 145	Glenmark Pharmaceuticals Distributor s.r.o. Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals sro. Glenmark Pharmaceuticals sro.	Fellow Subsidiary Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements) Service Income Received		Not appl Not appl				 <u> </u>	_
145	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals sro.	Fellow Subsidiary	Payable		Not appl Not appl		619.61	322.69		-
147	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Expenses Paid by others on our behalf		Not appl					$\square$
148 149	Glenmark Pharmaceuticals Distributor s.r.o. Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary Fellow Subsidiary	Payable Expenses paid on behalf of others	-	Not appl Not appl		-	0.02	 	+
150	Glenmark Pharmaceuticals Distributor s.r.o.	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Receivable		Not appl	able	-	0.01		
151 152	Glenmark Pharmaceuticals Distributor s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Specialty SA Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary Fellow Subsidiary	Receivable Sale of material & services		Not appl Not appl		0.03	-	 ——	_
152	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals SK SKO Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary	Expenses paid on behalf of others		Not appl Not appl				+-	+
154	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary	Receivable		Not appl		365.53	432.90		
155 156	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals SK SRO Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary Fellow Subsidiary	Service Income Received Expenses Paid by others on our behalf		Not appl Not appl				 ——	
157	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary	Payable		Not appl	able	114.96	100.42		
158	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Service Income Received Purchase of Fixed Assets		Not appl				 <u> </u>	_
159 160	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary Fellow Subsidiary	Expenses Paid by others on our behalf		Not appl Not appl				+-	+
	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Payable		Not appl		64.26	28.76	$ \rightarrow $	エ
	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary Fellow Subsidiary	Sale of material & services Expenses paid on behalf of others		Not appl Not appl				 	-
164	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Receivable		Not appl	able	16.31	152.31		-
165	Glenmark Pharmaceuticals s.r.o.	Viso Farmaceutica S.L.U. Viso Farmaceutica S.L.U.	Fellow Subsidiary	Sale of material & services	-	Not appl Not appl				 ——	_
166 167	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Viso Farmaceutica S.L.U. Viso Farmaceutica S.L.U.	Fellow Subsidiary Fellow Subsidiary	Expenses paid on behalf of others Receivable		Not appl Not appl		42.09	58.10	 +	+
	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals BV	Fellow Subsidiary	Service Expenses		Not appl	able 5.32				
169 170	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals BV Glenmark Pharmaceuticals BV	Fellow Subsidiary Fellow Subsidiary	Payable Sale of material & services		Not appl Not appl		2.47	7.56	 -+-	+
171	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals BV	Fellow Subsidiary	Expenses paid on behalf of others		Not appl	able 3.03				土
172	Glenmark Pharmaceuticals s.r.o.	Glenmark Pharmaceuticals BV	Fellow Subsidiary	Receivable Expenses Paid by others on our behalf		Not appl		136.18	152.19		$\mp$
173 174	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Nordics AB Glenmark Nordics AB	Fellow Subsidiary Fellow Subsidiary	Expenses Paid by others on our behalf Sale of material & services	1	Not appl Not appl				 +-	+
175	Glenmark Pharmaceuticals s.r.o.	Glenmark Nordics AB	Fellow Subsidiary	Expenses paid on behalf of others	1	Not appl	able 8.35				丁
176 177	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Nordics AB Glenmark Arzneimittel GmbH	Fellow Subsidiary Fellow Subsidiary	Receivable Purchase of Fixed Assets		Not appl Not appl		425.02	374.68	 -+-	+
178	Glenmark Pharmaceuticals s.r.o.	Glenmark Arzneimittel GmbH	Fellow Subsidiary	Expenses Paid by others on our behalf		Not appl	able 22.06				t
179	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Arzneimittel GmbH	Fellow Subsidiary	Payable Sale of material & services	-	Not appl Not appl		113.11	3.05	 ——	_
180	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Arzneimittel GmbH Glenmark Arzneimittel GmbH	Fellow Subsidiary Fellow Subsidiary	Expenses paid on behalf of others		Not appl Not appl				+-	+
182	Glenmark Pharmaceuticals s.r.o.	Glenmark Arzneimittel GmbH	Fellow Subsidiary	Receivable		Not appl	able	236.33	267.35		コ
183 184	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals s.r.o.	Glenmark Specialty SA Glenmark Specialty SA	Fellow Subsidiary Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements) Payable		Not appl Not appl		48.60	61.41	 -+-	+
185	Glenmark Pharmaceuticals s.r.o.	Glenmark Specialty SA Glenmark Specialty SA	Fellow Subsidiary	Sale of material & services		Not appl	able 9.91				
	Glenmark Pharmaceuticals s.r.o.	Glenmark Specialty SA	Fellow Subsidiary	Receivable		Not appl		6.02	4.18		Ŧ
	Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK s.r.o.	Glenmark Generics S.A Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary Fellow Subsidiary	Receivable Expenses Paid by others on our behalf	+	Not appl Not appl		2.09	1.98	 +-	+
189	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Pharmaceuticals SK SRO	Fellow Subsidiary	Expenses Paid on behalf		Not appl	able 0.02				二
190 191	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Glenmark Speciality SA Glenmark Speciality SA	Fellow Subsidiary Fellow Subsidiary	Service Income Receivable	+	Not appl Not appl		22.30	26.38	 -+-	+
191	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Glenmark Speciality SA Glenmark Arzneimittel GmbH	Fellow Subsidiary Fellow Subsidiary	Sale of material & services		Not appl Not appl		22.30	20.38		_
193	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Arzneimittel GmbH	Fellow Subsidiary	Expenses Paid on behalf		Not appl	able 4.17				Ŧ
194 195	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Glenmark Arzneimittel GmbH Glenmark Pharmaceuticals B.V.	Fellow Subsidiary Fellow Subsidiary	Receivable Expenses Paid on behalf	+	Not appl Not appl		43.83	46.35	 -+-	+
196	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Pharmaceuticals B.V.	Fellow Subsidiary	Receivable		Not appl	able	0.42	0.75		t
	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Farmaceutica Ltda	Fellow Subsidiary	Receivable Sale of material & services	+	Not appl Not appl		3.29	3.01	 	$-\Gamma$
198 199	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Viso Farmacéutica S.L.U Viso Farmacéutica S.L.U	Fellow Subsidiary Fellow Subsidiary	Sale of material & services Expenses Paid on behalf	1	Not appl Not appl				 +-	+
200	Glenmark Pharmaceuticals Europe Ltd.	Viso Farmacéutica S.L.U	Fellow Subsidiary	Receivable		Not appl	able	38.81	36.91		エ
201 202	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Glenmark Nordics AB Glenmark Nordics AB	Fellow Subsidiary Fellow Subsidiary	Expenses Paid on behalf Receivable	-	Not appl Not appl		264.69	251.27	 <u> </u>	+
203	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Life Sciences Limited	Fellow Subsidiary	Service Income		Not appl	able 2.21				$\pm$
	Glenmark Pharmaceuticals Europe Ltd.	Glenmark Life Sciences Limited	Fellow Subsidiary	Receivable		Not appl		1.13	3.13		$-\Gamma$
			Fallow Cult - Marca	Exponence Raid on bohalf							
205	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Glenmark Pharmaceuticals Inc Glenmark Pharmaceuticals Inc	Fellow Subsidiary Fellow Subsidiary	Expenses Paid on behalf Receivable		Not appl Not appl		0.00	1.66	 $\rightarrow$	+

	+						
Desc         Desc         Desc         Desc         Desc           Image: Problem in the section of t	+						
	ţ						
Image         Image         Image         Image         Image           Image	+						
Image: Section of the section of t	╈						
Image: Section of the section of t							
Not         Not         Not         Not	╋						
	╈						
Note         Note         Note         Note	╋						
Note         National         National         National           National         National         National         National         National <td>╈</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	╈						
Image: Section of the section of t							
Image: Section of the section of t	╋						
Image: Section of the section of t	╈						
LoanS%Not fixedUnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanS%UnsecuredLoanLo							
Image: state         Image: state         Image: state           Image: state         Image: state         I	╇						
Note </td <td>╈</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	╈						
	t						
Image: State in the second							
Image: Section of the section of t	+						
Image: Section of the section of t	+						
Image: state of the state of	t						
AndAndAndAndAndAndAndAndAndAndAndAndIoan5%Not fixedUnsecuredBusiness purposeIoan5%Not fixedUnsecuredBusiness purposeIoan5%Not fixedUnsecuredBusiness purposeIoan5%Not fixedUnsecuredBusiness purposeIoan6AndAndAndIoanAndAndAndAndIoanAn	Ţ						
IndexIndexIndexIndexIndexIndexLoan5%Not fixedUnsecuredBusiness purposeIndex <t< td=""><td>╀</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	╀						
IndexIndexIndexIndexLoanS%Not fixedUnsecuredBusiness purposeIndex <td>+</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	+						
LoanS%Not fixedUnsecuredBusiness purposeLoanS%Not fixedUnsecuredBusiness purposeIII </td <td>t</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	t						
LanS%Not faceBusiness purposeImage: Signal sectorS%UnsecuredBusiness purposeImage: Signal sectorImage: Sign	Ţ						
compmresult interconstructconstructconstructImage: section of the section of	.	030	5%	Not fixed	Unsecured	Business purposo	
Image: Section of the section of t	ľ	Judii	570	NUL HXEU	onsecuteu	pasiliess haihose	
Image: state of the state of	t						
III	Ţ						
Image: style s	╀						
	╈						
Image: Section of the section of t	t						
Image: Section of the section of t							
Image: Section of the section of t	╇						
Image: Section of the section of t	╋						
Image: Section of the section of t	t						
Image: state of the state of							
Image: Section of the section of t	╋						-
Image: Section of the section of t	╋						
Image: state of the state of	t						
Image: state of the state of							
Image: Section of the section of t	╇						
Image: state of the state o	╈						
Image: section of the section of t	t						
Image: set of the							
	╋						-
	╈						
Image: section of the section of t	t						
Image: section of the section of t	L						
Image: section of the section of t	+						
	╉						
Image: state	t						
	ŗ						
	+						
	+						
	t						
	Ļ						
	╀						
	ϯ						
Image: state	ļ						
Image: state	Ļ						
	╀						
	t						
Image: state	Ţ						
	+						
	+						
	t						
	Ţ						
	╀						
	╉						
	t						
	Ţ						
	Ļ						
	+						
	t						
	Ţ						
	Ļ						
	╀						
	$\dagger$						
	t						
	Ţ						
	╀						
	+						
	T						

207 Glenmark Pharmaceuticals Europe Ltd. 208 Glenmark Pharmaceuticals Europe Ltd.	Glenmark Impex LLC Glenmark Generics SA	Fellow Subsidiary Fellow Subsidiary	Receivable Receivable	-		Not applicable Not applicable		0.45	0.41		—	—
209 Glenmark Pharmaceuticals Europe Ltd.	Glenmark Pharmaceuticals Mexico, S.A. DE C.V.	Fellow Subsidiary	Receivable			Not applicable		0.32	0.48			$\pm$
210 Glenmark Pharmaceuticals Europe Ltd. 211 Glenmark Pharmaceuticals Europe Ltd.	Glenmark Arzneimittel GmbH Glenmark Arzneimittel GmbH	Fellow Subsidiary Fellow Subsidiary	Interest Expense Loan pavable	-		Not applicable Not applicable	43.10	3,658.65	3,483.67			-
211 Glenmark Pharmaceuticals Europe Ltd. 212 Glenmark Holding S.A	Glenmark Arzneimittel GmbH Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary	Loan taken			Not applicable	695.57	3,038.03	3,463.07			Lo
213 Glenmark Holding S.A 214 Glenmark Holding S.A	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Europe Ltd.	Fellow Subsidiary Fellow Subsidiary	Interest Payable on Loan taken Loan payable			Not applicable Not applicable	0.13	0.00	724.05			
214 Glenmark Holding SA 215 Glenmark Holding SA	Glenmark Specialty SA	Fellow Subsidiary	Payable			Not applicable		8.57	0.00			
216 Glenmark Holding SA	Glenmark Farmaceutica, Ltda	Fellow Subsidiary	Loan Receivable			Not applicable		3.89	4.20			Lo
217         Glenmark South Africa (Pty) Ltd.           218         Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Glenmark Pharmaceuticals South Africa (Pty) Ltd. Glenmark Specialty SA	Fellow Subsidiary Fellow Subsidiary	Loan given Purchase of materials & services (inclusive reimbursements)	_		Not applicable Not applicable	98.80	490.46	427.14		+	Lo
219 Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Glenmark Specialty SA	Fellow Subsidiary	Payable			Not applicable	4.24	41.81	99.87		$\square$	_
220 Glenmark Pharmaceuticals South Africa (Pty) Ltd. 221 Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Glenmark Pharmaceuticals Kenya Ltd Glenmark Pharmaceuticals Kenya Ltd	Fellow Subsidiary Fellow Subsidiary	Sale of material & services Receivable			Not applicable Not applicable	1.34	2.51	1.33		<u> </u>	
222 Glenmark Pharmaceuticals Egypt S.A.E.	Glenmark Pharmaceuticals Kenya Ltd	Fellow Subsidiary	Receivable			Not applicable		1.87	2.01			4
223 Glenmark Pharmaceuticals Kenya Ltd 224 Glenmark Pharmaceuticals Kenya Ltd	Glenmark Generics S. A. Glenmark Generics S. A.	Fellow Subsidiary Fellow Subsidiary	Payable Receivable	-	<u> </u>	Not applicable Not applicable	4.86	4.72	0.00	<del>_</del>	<u> </u>	
225 Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Inc.	Fellow Subsidiary	Sale of material & services			500.00	181.48					
226 Glenmark Life Sciences Limited 227 Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Inc. Glenmark Pharmaceuticals Inc.	Fellow Subsidiary Fellow Subsidiary	Receivable Expenses Reimbursed			Not applicable Not applicable	0.24	285.38	219.80		_	
228 Glenmark Life Sciences Limited	Viso Farmaceutica S.L.U.	Fellow Subsidiary	Purchase of materials & services (inclusive reimbursements)			35.00	4.77					
229 Glenmark Life Sciences Limited 230 Glenmark Life Sciences Limited	Viso Farmaceutica S.L.U.	Fellow Subsidiary	Payable Purchase of materials & services (inclusive reimbursements)	_		Not applicable 50.00	26.21	3.59	8.11	<del>_</del>	<u> </u>	
230 Glenmark Life Sciences Limited 231 Glenmark Life Sciences Limited	Glenmark Farmaceutica Ltda. Glenmark Farmaceutica Ltda.	Fellow Subsidiary Fellow Subsidiary	Payable	-		Not applicable	20.21	31.99	24.37			-
232 Glenmark Life Sciences Limited	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Expenses Reimbursed			Not applicable	1.18				$\square$	_
Glenmark Life Sciences Limited	Glenmark Foundation	Enterprises over which significant influence exercised by key management personnel/directors	Expenditure incurred for CSR activities			70.00	10.00	0.00	0.00			
234 Glenmark Life Sciences Limited 235 Glenmark Life Sciences Limited	Dr. Yasir Rawjee Mr. Tushar Mistry	MD & CEO Chief Financial Officer	Remuneration Remuneration	_		Not applicable Not applicable	22.79				——	+
236 Glenmark Life Sciences Limited	Mr. Sumantra Mitra	Executive Director	Remuneration		ļ	Not applicable	8.74				—	ヰ
237 Glenmark Life Sciences Limited	Mr. Rudalf Corriea	Company Secretary & Compliance Officer	Remuneration			Not applicable	0.93					
238 Glenmark Life Sciences Limited	Mrs. Manju Agarwal	Independent Director	Sitting Fees			Not applicable	0.60					$\pm$
239 Glenmark Life Sciences Limited	Mr. T L Easwar	Independent Director	Sitting Fees		+ $ +$	Not applicable	0.50					$\mp$
240 Glenmark Life Sciences Limited 241 Glenmark Life Sciences Limited	Ms. Gita Nayyar Mr. Sridhar Gorthi	Independent Director Independent Director	Sitting Fees Sitting Fees			Not applicable Not applicable	0.50			<del> </del>	+-	+
242 Glenmark Life Sciences Limited	Mr. Bhavesh Pujara	Chief Financial Officer	Remuneration			Not applicable	4.68					1
243     Glenmark Pharmaceuticals Canada Inc.       244     Glenmark Pharmaceuticals Canada Inc.	Glenmark Phamraceuticals Inc USA Glenmark Phamraceuticals Inc USA	Fellow Subsidiary Fellow Subsidiary	Expenses paid on behalf of others Payable		<u>├</u>	Not applicable Not applicable	2.18	1.86	3.95		+	+
245 Glenmark Therapeutics Inc.	Glenmark Pharmaceuticals Inc.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)			Not applicable	1.24					$\pm$
246         Glenmark Therapeutics Inc.           247         Glenmark Phamraceuticals Inc	Glenmark Pharmaceuticals Inc. Glenmark Generics S.A	Fellow Subsidiary Fellow Subsidiary	Payable Receivable		<u>                                     </u>	Not applicable Not applicable		1.16	1.29 8.60		+-	F
247 Glenmark Phamraceuticals Inc 248 Glenmark Phamraceuticals Inc	Glenmark Generics S.A Glenmark Specialty SA	Fellow Subsidiary Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)	_		Not applicable Not applicable	1,868.49	7.97	8.60		——	+
249 Glenmark Phamraceuticals Inc	Glenmark Specialty SA	Fellow Subsidiary	Service Income Received			Not applicable	116.83					$\square$
250 Glenmark Phamraceuticals Inc 251 Glenmark Phamraceuticals Inc	Glenmark Specialty SA Glenmark Farmaceutica Ltda	Fellow Subsidiary Fellow Subsidiary	Payable Sale of Fixed Assets			Not applicable Not applicable	18.11	2,901.32	2,850.51			-
252 Glenmark Phamraceuticals Inc	Glenmark Farmaceutica Ltda	Fellow Subsidiary	Receivable			Not applicable		14.42	34.42			_
253 Glenmark Phamraceuticals Inc	Glenmark Holding SA	Fellow Subsidiary	Loan taken		<u>↓                                      </u>	Not applicable	9,515.02				_	Lo
254 Glenmark Phamraceuticals Inc 255 Glenmark Phamraceuticals Inc	Glenmark Holding SA Glenmark Holding SA	Fellow Subsidiary Fellow Subsidiary	Loan repaid Interest Payable on Loan taken	_		Not applicable Not applicable	7751.70 155.07				——	- 10
256 Glenmark Phamraceuticals Inc	Glenmark Holding SA	Fellow Subsidiary	Loan payable			Not applicable		106.10	1,996.54			Lo
257 Glenmark Pharmaceuticals Peru S.A 258 Glenmark Pharmaceuticals Peru S.A	Glenmark Farmaceutica Ltda. Glenmark Farmaceutica Ltda.	Fellow Subsidiary Fellow Subsidiary	Purchase of Goods and Services (Net of Returns) Payable			Not applicable Not applicable	2.06	0.11	3.60		——	-
259 Glenmark Pharmaceuticals Peru S.A	Glenmark Speciality S.A.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)			Not applicable	4.26					-
260 Glenmark Pharmaceuticals Peru S.A 261 Glenmark Pharmaceuticals Peru S.A	Glenmark Speciality S.A. Glenmark Pharmaceuticals Colombia SAS	Fellow Subsidiary Fellow Subsidiary	Receivable Sale of Goods and Service			Not applicable Not applicable	0.73	3.14	4.49		<u> </u>	+
261 Glenmark Pharmaceuticals Peru S.A 262 Glenmark Pharmaceuticals Peru S.A	Glenmark Pharmaceuticals Colombia SAS	Fellow Subsidiary	Receivable	-		Not applicable	0.73	0.00	0.77			-
263 Glenmark Pharmaceuticals México, S.A. de C.V.	Glenmark Generics S.A.	Fellow Subsidiary	Purchase of Goods and Services (Net of Returns)			Not applicable	47.10				$\square$	_
264 Glenmark Pharmaceuticals México, S.A. de C.V. 265 Glenmark Pharmaceuticals México, S.A. de C.V.	Glenmark Generics S.A. Glenmark Farmaceutica Ltda.	Fellow Subsidiary Fellow Subsidiary	Receivable Purchase of Goods and Services (Net of Returns)	-	<u> </u>	Not applicable Not applicable	1.81	3.31	6.30	<del>_</del>	<u> </u>	
266 Glenmark Pharmaceuticals México, S.A. de C.V.	Glenmark Farmaceutica Ltda.	Fellow Subsidiary	Receivable			Not applicable		7.86	6.11			
267 Glenmark Impex LLC 268 Glenmark Impex LLC	Glenmark Speciality SA Glenmark Speciality SA	Fellow Subsidiary Fellow Subsidiary	Purchase of Goods and Services (Net of Returns) Receivable			Not applicable Not applicable	24.79	108.36	38.79		_	+
269 Glenmark Speciality SA	Glenmark Pharmaceuticals Ecuador S.A.	Fellow Subsidiary	Sale of Goods and Service			Not applicable	6.14	100.50	30.75			+
270 Glenmark Speciality SA	Glenmark Pharmaceuticals Ecuador S.A.	Fellow Subsidiary	Receivable			Not applicable		8.32			$\square$	-
271 Glenmark Speciality SA 272 Glenmark Speciality SA	Glenmark Holding SA Glenmark Holding SA	Fellow Subsidiary Fellow Subsidiary	Loan Payable Interest Paid	-	<u> </u>	Not applicable Not applicable	381.96	16,713.02	14,785.04	<del>_</del>	<u> </u>	
273 Glenmark Pharmaceuticals Europe Ltd.	Oliver Bourne	Director	Remuneration			Not applicable	14.40					
274     Glenmark Pharmaceuticals S.R.O.       275     Glenmark Pharmaceuticals S.R.O.	Andrzej Gondek Filip Ludvik	Director	Remuneration Remuneration	_		Not applicable Not applicable	18.34 5.17				<u> </u>	_
275 Glenmark Pharmaceuticals S.R.O. 276 Glenmark Pharmaceuticals S.R.O.	Petr Podlipny	Director Director	Remuneration	-		Not applicable	6.26					-
277 Glenmark Pharmaceuticals SK, S.R.O.	Andrzej Gondek	Director	Remuneration			Not applicable	18.34					7
278 Glenmark Pharmaceuticals SK, S.R.O. 279 Glenmark Pharmaceuticals Inc. USA	Pavel Zachrla Laura Lester	Director Director	Remuneration Remuneration		+ +	Not applicable Not applicable	11.09 26.03			<del> </del>	+-	+
280 Glenmark Pharmaceuticals Inc. USA	Sanjeev Krishan	Director	Remuneration			Not applicable	65.08					二
281 Glenmark Pharmaceuticals Inc. 282 Glenmark Pharmaceuticals Inc.	Saira Ramasastry Rajeev Sharma	Other related party Director	Consulting Fees Remuneration		├	Not applicable Not applicable	1.08 18.29				+-	+
282 Glenmark Pharmaceuticals Inc. 283 Glenmark Pharmaceuticals Inc.	Sanjeev Krishan	Director	Remuneration			Not applicable	65.08			<u> </u>		_
284 Glenmark Farmaceutica Ltda	Carlos Aguiar	Director	Remuneration			Not applicable	9.91					7
285 Glenmark Farmaceutica Ltda 286 Glenmark Farmaceutica Ltda	Neeraj Gupta Ana Sarmento	Director Director	Remuneration Remuneration		<u>├</u>	Not applicable Not applicable	8.11 4.41			—— <del> </del>	+	+
287 Glenmark Generics S.A	Victor Rodolfo Bertuccio	Director	Remuneration			Not applicable	7.03					$\pm$
288 Glenmark Generics S.A 289 Glenmark Generics S.A	Gustavo Andrés Carrera Carlos Eduardo Vieira de Aguiar	Director Director	Remuneration Remuneration		├	Not applicable Not applicable	5.90 9.91				+-	+
289 Glenmark Generics S.A 290 Glenmark Pharmaceuticals Mexico, S.A. DE C.V.	Mariano Rozada	Director	Remuneration			Not applicable	17.03			<u> </u>		_
291 Glenmark Pharmaceuticals Mexico, S.A. DE C.V.	Catalino Bocanegra	Director	Remuneration			Not applicable	5.14				—	エ
292 under Glenmark Pharmaceuticals Europe Ltd. 293 Glenmark Pharmaceuticals Peru SAC	Robson Tarciso de Faria Mauricio Guerra	Director	Remuneration Remuneration		+ +	Not applicable Not applicable	10.52				+-	+
294 Glenmark Pharmaceuticals Colombia SAS, Colombia	Mariano Hugo Rozada	Director	Remuneration			Not applicable	17.03					$\pm$
295 Glenmark Pharmaceuticals Colombia SAS, Colombia 296 Glenmark Pharmaceuticals FZE	Mauricio Guerra Martinez Dr Alok Chopra	Director Director	Remuneration Remuneration		├	Not applicable Not applicable	5.27				+-	+
296 Glenmark Pharmaceuticals FZE 297 Glenmark Pharmaceuticals FZE	Dr Alok Chopra Csaba Kantor	Director	Remuneration			Not applicable	51.23			+		_+
298 Glenmark Pharmaceuticals Kenya Ltd	Catherine Maina	Director	Remuneration			Not applicable	1.77					7
299 Glenmark Pharmaceuticals Distribution s.r.o. 300 Glenmark Pharmaceuticals Nordic AB	Marián Kolmokov Henric Juserius	Director Director	Remuneration Remuneration	-	<u>├</u>	Not applicable Not applicable	11.38			—	+-	+
301 Glenmark Pharmaceuticals Inc.	Bernard Munos	Director	Consulting Fees			Not applicable	1.57					土
302         Glenmark Pharmaceuticals Inc.           303         Glenmark Pharmaceuticals Europe Ltd.	Sona Saira Ramasastry Dipankar Bhattacharjee	Other Related Party Other Related Party	Consulting Fees Consulting Fees		<b>├</b> ──┤	Not applicable Not applicable	2.15		]		<u> </u>	+
303 EDITION FIGUIDALEULICAIS EULODE LTO.	Hale & Tempest	Other Related Party Other Related Party	Consulting Fees			Not applicable	0.20			+		_+
304 Glenmark Holding S.A.		Director	Remuneration			Not applicable	4.52					エ
304       Glenmark Holding S.A.         305       Glenmark Ukraine LLC	Sergey Goryslavets		Remuneration			Not applicable	10.62				<del></del>	-
304     Glenmark Holding S.A.       305     Glenmark Ukraine LLC       306     Glenmark Arzneimittel Gmbh	Barbara Wilhelm	Director Fellow Subsidiary	Investment in Share Capital		1 1	Not applicable	3,112.55			1		
304     Glenmark Holding S.A.       305     Glenmark Ukraine LLC       306     Glenmark Arzneimittel Gmbh       307     Glenmark Holding S.A.       308     Glenmark Holding S.A.	Barbara Wilhelm Ichnos Sciences Inc. Glenmark Farmacêutica Ltda	Fellow Subsidiary Fellow Subsidiary	Investment in Share Capital				119.30					
304     Glenmark Holding S.A.       305     Glenmark Utraine LLC       306     Glenmark Arzneimittel Gmbh       307     Glenmark Holding S.A.       308     Glenmark Holding S.A.       309     Glenmark Holding S.A.	Barbara Wilhelm Ichnos Sciences Inc. Glenmark Farmacéutica Ltda Glenmark Generics SA	Fellow Subsidiary Fellow Subsidiary Fellow Subsidiary	Investment in Share Capital Investment in Share Capital			Not applicable		9 020 13	0.155.00	<u> </u>	+	╡
304     Glenmark Holding S.A.       305     Glenmark Ukraine LLC       306     Glenmark Arzneimittel Gmbh       307     Glenmark Holding S.A.       308     Glenmark Holding S.A.	Barbara Wilhelm Ichnos Sciences Inc. Glenmark Farmacêutica Ltda	Fellow Subsidiary Fellow Subsidiary	Investment in Share Capital				119.30	8,939.13 12,679.07	9,166.98 12,798.37		+	
304     Glenmark Holding S.A.       305     Glenmark Utraine LLC       306     Glenmark Arzneimittel Gmbh       307     Glenmark Holding S.A.       308     Glenmark Holding S.A.       309     Glenmark Holding S.A.       301     Glenmark Holding S.A.	Barbara Wilhelm Ichnos Sciences Inc. Glenmark Farmacêutica Ltda Glenmark Generics SA Glenmark Generics SA	Fellow Subsidiary Fellow Subsidiary Fellow Subsidiary Fellow Subsidiary	Investment in Share Capital Investment in Share Capital Investment			Not applicable Not applicable	119.30					

_						-
_						
	1.000	euribor+2%	Nat fired	Unsecured	Dusiness nur-	
-	Loan Loan	3.50%	Not fixed Not fixed	Unsecured	Business purpose Business purpose	
_	Loan	3.50%	Not fixed	Unsecured	Business purpose	
	Loan	5%	Not fixed	Unsecured	Business purpose	
	Loan	0%	Not fixed	Unsecured	Business purpose	
-						
_						
_						
_						
_						
_						
_						
_						
-						
_						
	Loan	5%	3 Years	Unsecured	Business purpose	
	Loan	5%	3 Years	Unsecured	Business purpose	
_	Loan	5%	3 Years	Unsecured	Business purpose	
-						
_						
_						
-	Loan	5%	Not fixed	Unsecured	Business purpose	
	20011		Hot liked	onsecured	Busiless parpose	
-						
_						
	Investment	Not applicable	Not applicable	Not applicable	Business purpose	
	Investment	Not applicable	Not applicable	Not applicable	Business purpose	
	Investment	Not applicable	Not applicable	Not applicable	Business purpose	
	Investment	Not applicable	Not applicable	Not applicable	Business purpose	
	Investment	Not applicable	Not applicable	Not applicable	Business purpose	

315 (	Glenmark Pharmaceuticals Limited	G	Glenmark Pharmaceuticals Peru SAC.	Fellow Subsidiary	Investment		Not applicable	772.06	827.79	1

- Notes:
  All Related Party Transactions entered during the period were in ordinary course of the business and on arm's length basis.
  Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.
  Share Based Payment Expenses pertaining to Key Mananerial Personnel is not included.
  Balances have been aggregated entity wise for all type of transactions and shown as net receivable/(payable)
  As per the guidance note for disclosure of related party transactions dated 25th April, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
  The value of the related party transaction denotes that Committee/ Board of Directors, as applicable, for financial year 2022-23.
  All transactions in foreign currency, wherever applicable, have been converted and disclosed in INR.
  Difference in opening and closing balances is on account of exchange rate fluctuation.
  All figures in this disclosure are rounded off up to two decimals.

1			Ţ]